Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC — Stella

Recruiting

Back to NSCLC (Non-small Cell Lung Cancer) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

2nd Affiliated Hospital, School of Medicine, Hangzhou, Zhejiang

Key details

Phase

Safety & dosing

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Collaborators

Zhengzhou University, Hunan Cancer Hospital - the Affiliated Cancer Hospital of Xiangya school of Medicine, Central South University

Enrollment target

~78 participants

Started

October 2024

Primary completion

June 2027

Age range

18 Years and older

Last updated March 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov